Kelsey Goodwin
Stock Analyst at Guggenheim
(0.52)
# 3,833
Out of 4,711 analysts
15
Total ratings
30%
Success rate
-13.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GNLX Genelux | Initiates: Buy | $8 | $2.27 | +252.42% | 1 | Oct 29, 2024 | |
| NUVL Nuvalent | Maintains: Buy | $99 → $105 | $84.22 | +24.67% | 2 | Sep 16, 2024 | |
| URGN UroGen Pharma | Initiates: Buy | $40 | $10.64 | +275.94% | 1 | Aug 22, 2024 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $3.18 | - | 1 | Jul 31, 2024 | |
| TSVT 2seventy bio | Downgrades: Neutral | n/a | $3.14 | - | 4 | Sep 13, 2023 | |
| ACLX Arcellx | Maintains: Buy | n/a | $75.54 | - | 3 | Jun 20, 2023 | |
| LEGN Legend Biotech | Initiates: Neutral | n/a | $34.08 | - | 1 | Oct 31, 2022 | |
| IOVA Iovance Biotherapeutics | Initiates: Neutral | n/a | $7.38 | - | 1 | Oct 31, 2022 | |
| IPSC Century Therapeutics | Initiates: Buy | $15 | $1.10 | +1,263.64% | 1 | Oct 31, 2022 |
Genelux
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $2.27
Upside: +252.42%
Nuvalent
Sep 16, 2024
Maintains: Buy
Price Target: $99 → $105
Current: $84.22
Upside: +24.67%
UroGen Pharma
Aug 22, 2024
Initiates: Buy
Price Target: $40
Current: $10.64
Upside: +275.94%
MacroGenics
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.18
Upside: -
2seventy bio
Sep 13, 2023
Downgrades: Neutral
Price Target: n/a
Current: $3.14
Upside: -
Arcellx
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $75.54
Upside: -
Legend Biotech
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $34.08
Upside: -
Iovance Biotherapeutics
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $7.38
Upside: -
Century Therapeutics
Oct 31, 2022
Initiates: Buy
Price Target: $15
Current: $1.10
Upside: +1,263.64%